158 related articles for article (PubMed ID: 28633161)
1. [Insulin secretion in the early phase of type 1 diabetes mellitus (T1DM) and new hopes for maintaining it through therapy].
Żalińska M; Szmigiero-Kawko M; Brandt A; Trzonkowski P; Myśliwiec M
Pediatr Endocrinol Diabetes Metab; 2016; 22(3):. PubMed ID: 28633161
[TBL] [Abstract][Full Text] [Related]
2. Stem cell therapy emerging as the key player in treating type 1 diabetes mellitus.
Vanikar AV; Trivedi HL; Thakkar UG
Cytotherapy; 2016 Sep; 18(9):1077-86. PubMed ID: 27424148
[TBL] [Abstract][Full Text] [Related]
3. Prolactin as an Adjunct for Type 1 Diabetes Immunotherapy.
Hyslop CM; Tsai S; Shrivastava V; Santamaria P; Huang C
Endocrinology; 2016 Jan; 157(1):150-65. PubMed ID: 26512750
[TBL] [Abstract][Full Text] [Related]
4. Protein Kinase CK2-A Putative Target for the Therapy of Diabetes Mellitus?
Ampofo E; Nalbach L; Menger MD; Montenarh M; Götz C
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500224
[TBL] [Abstract][Full Text] [Related]
5. Modulation of the pancreatic islet-stress axis as a novel potential therapeutic target in diabetes mellitus.
Ludwig B; Barthel A; Reichel A; Block NL; Ludwig S; Schally AV; Bornstein SR
Vitam Horm; 2014; 95():195-222. PubMed ID: 24559919
[TBL] [Abstract][Full Text] [Related]
6. Antiaging Gene Klotho Attenuates Pancreatic β-Cell Apoptosis in Type 1 Diabetes.
Lin Y; Sun Z
Diabetes; 2015 Dec; 64(12):4298-311. PubMed ID: 26340932
[TBL] [Abstract][Full Text] [Related]
7. Similar weight-adjusted insulin secretion and insulin sensitivity in short-duration late autoimmune diabetes of adulthood (LADA) and type 2 diabetes: Action LADA 9 [corrected].
Juhl CB; Bradley U; Holst JJ; Leslie RD; Yderstraede KB; Hunter S;
Diabet Med; 2014 Aug; 31(8):941-5. PubMed ID: 24628669
[TBL] [Abstract][Full Text] [Related]
8. Insulin-secreting cells derived from stem cells: clinical perspectives, hypes and hopes.
Roche E; Reig JA; Campos A; Paredes B; Isaac JR; Lim S; Calne RY; Soria B
Transpl Immunol; 2005 Dec; 15(2):113-29. PubMed ID: 16412956
[TBL] [Abstract][Full Text] [Related]
9. Biphasic decline of β-cell function with age in euglycemic nonobese diabetic mice parallels diabetes onset.
Cechin SR; Lopez-Ocejo O; Karpinsky-Semper D; Buchwald P
IUBMB Life; 2015 Aug; 67(8):634-44. PubMed ID: 26099053
[TBL] [Abstract][Full Text] [Related]
10. GAD-alum (Diamyd)--a new concept for preservation of residual insulin secretion.
Ludvigsson J
Expert Opin Biol Ther; 2010 May; 10(5):787-99. PubMed ID: 20230187
[TBL] [Abstract][Full Text] [Related]
11. Diabetes type 1: Can it be treated as an autoimmune disorder?
Vallianou NG; Stratigou T; Geladari E; Tessier CM; Mantzoros CS; Dalamaga M
Rev Endocr Metab Disord; 2021 Dec; 22(4):859-876. PubMed ID: 33730229
[TBL] [Abstract][Full Text] [Related]
12. Exercise and Type 1 Diabetes.
Lu X; Zhao C
Adv Exp Med Biol; 2020; 1228():107-121. PubMed ID: 32342453
[TBL] [Abstract][Full Text] [Related]
13. Original hypothesis: Extracorporeal shockwaves as a homeostatic autoimmune restorative treatment (HART) for Type 1 diabetes mellitus.
Craig K; d'Agostino C; Poratt D; Walker M
Med Hypotheses; 2014 Sep; 83(3):250-3. PubMed ID: 24947195
[TBL] [Abstract][Full Text] [Related]
14. Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results.
Eldor R; Kassem S; Raz I
Diabetes Metab Res Rev; 2009 May; 25(4):316-20. PubMed ID: 19267355
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus.
Guglielmi C; Williams SR; Del Toro R; Pozzilli P
Expert Opin Biol Ther; 2016 Jun; 16(6):841-6. PubMed ID: 27145230
[TBL] [Abstract][Full Text] [Related]
16. Insulin secretion in patients with latent autoimmune diabetes (LADA): half way between type 1 and type 2 diabetes: action LADA 9.
Hernandez M; Mollo A; Marsal JR; Esquerda A; Capel I; Puig-Domingo M; Pozzilli P; de Leiva A; Mauricio D;
BMC Endocr Disord; 2015 Jan; 15():1. PubMed ID: 25572256
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of preserved insulin secretion in children and adolescents with type 1 diabetes].
Wegner O; Wyka K; Fendler W; Zmysłowska A; Młynarski W
Pediatr Endocrinol Diabetes Metab; 2010; 16(2):67-71. PubMed ID: 20813081
[TBL] [Abstract][Full Text] [Related]
18. MST1: a promising therapeutic target to restore functional beta cell mass in diabetes.
Ardestani A; Maedler K
Diabetologia; 2016 Sep; 59(9):1843-9. PubMed ID: 27053234
[TBL] [Abstract][Full Text] [Related]
19. Tissue inhibitor of metalloproteinase-2 inhibits T-cell infiltration and preserves pancreatic beta-cell function in an in vitro type 1 diabetes mellitus model.
Woods CC; Sundar K; Tessler C; Lebsack TW; Grainger L; Nielsen A; Bleich D; DeLuca D
J Autoimmun; 2006 Aug; 27(1):28-37. PubMed ID: 16765565
[TBL] [Abstract][Full Text] [Related]
20. Revisiting multiple models of progression of β-cell loss of function in type 1 diabetes: Significance for prevention and cure.
Li X; Cheng J; Zhou Z
J Diabetes; 2016 Jul; 8(4):460-9. PubMed ID: 26754489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
